Should aspirin be added for a patient with an acute ischemic stroke who is already on warfarin with a therapeutic INR?

Do Not Add Aspirin to Therapeutic Warfarin for Acute Ischemic Stroke

For a patient with acute ischemic stroke who is already on warfarin with a therapeutic INR, you should NOT routinely add aspirin. The guidelines explicitly recommend against this combination to avoid increased bleeding risk.

Key Recommendation

Antiplatelet agents should not be routinely added to warfarin in the interest of avoiding additional bleeding risk 1, 2. This is a Class III recommendation (Level C evidence), meaning it is potentially harmful.

Clinical Algorithm

Step 1: Verify the Clinical Scenario

• Confirm therapeutic INR (2.0-3.0 for most indications)
• Identify the indication for warfarin (atrial fibrillation, mechanical valve, etc.)
• Assess stroke mechanism (cardioembolic vs. other)

Step 2: Acute Management

• Continue warfarin at therapeutic INR
• Do NOT add aspirin routinely
• Aspirin in acute stroke is indicated for patients NOT on anticoagulation 3, 4

Step 3: Specific Exceptions Where Aspirin May Be Added

The guidelines identify only two specific scenarios where adding aspirin to warfarin is reasonable:

1. Acute MI with LV thrombus causing stroke: Aspirin up to 162 mg/day should be used concurrently with warfarin (INR 2.0-3.0) 1, 2 - Class I recommendation

2. Mechanical prosthetic heart valves with recurrent embolism DESPITE adequate anticoagulation: Adding aspirin 75-100 mg/day to warfarin (target INR 3.0, range 2.5-3.5) is reasonable 1 - Class IIa recommendation

3. Rheumatic mitral valve disease with recurrent embolism while on warfarin: Adding aspirin 81 mg/day may be indicated 1, 2 - Class IIa recommendation

Important Nuances

Why Not Add Aspirin?

The combination significantly increases bleeding risk without proven additional benefit in most cardioembolic stroke scenarios. The guidelines specifically state this for:

• Atrial fibrillation with therapeutic anticoagulation
• Rheumatic mitral valve disease (unless recurrent events occur)
• Most cardioembolic sources

The Subtherapeutic INR Situation

If the patient's INR is subtherapeutic (<2.0), this changes the picture:

• The stroke likely occurred due to inadequate anticoagulation 5
• Focus on optimizing warfarin dosing to achieve therapeutic INR
• Still do not routinely add aspirin
• Research shows patients with INR <2.0 are at much higher risk for ischemic events 5

Timing Considerations

For acute stroke management:

• Aspirin should be given within 24-48 hours for patients NOT on anticoagulation 3
• If thrombolysis is used, aspirin should NOT be given within 24 hours 3
• For patients already on warfarin with therapeutic INR, continue warfarin alone

Common Pitfalls to Avoid

1. Don't reflexively add aspirin because the patient had a stroke "despite" anticoagulation - if INR is therapeutic, adding aspirin increases bleeding risk without clear benefit

2. Don't confuse acute stroke management guidelines (which recommend aspirin for non-anticoagulated patients) with management of patients already on therapeutic anticoagulation

3. Don't assume "more is better" - dual therapy with warfarin plus aspirin has 3-4 times higher bleeding rates 6

4. Verify the INR was actually therapeutic at the time of stroke - subtherapeutic INR suggests inadequate anticoagulation, not treatment failure 5

The Evidence Base

The most recent comprehensive guideline 7 from 2021 maintains the position that antiplatelet agents should not be routinely added to warfarin. The WARIS II trial 6 demonstrated that while combination therapy reduced reinfarction, it significantly increased bleeding complications (4x major bleeding vs aspirin alone).

Bottom line: Continue warfarin alone at therapeutic INR unless the patient has one of the three specific exceptions listed above (acute MI with LV thrombus, mechanical valve with recurrent events despite adequate anticoagulation, or rheumatic mitral disease with recurrent events).